Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback